Merck KGaA Returns PKU Drugs To BioMarin To Focus On Cancer
This article was originally published in Scrip
Executive Summary
Merck KGaA is returning to BioMarin Pharmaceutical Inc the rights to the Kuvan (sapropterin) drug against rare genetic disorder PKU as the diversified German group seeks to exit non-core areas to focus on cancer, immunology and neurology.
You may also be interested in...
BioMarin Gets Second PKU Approval, Anticipates Slow Ramp-Up For Palynziq
Analysts say black box warning of anaphylaxis risk and REMS were anticipated. Company plans a gradual rollout of Palynziq, focusing first on Phase III clinical trial sites and patients.
Merck KGaA To Exit Biosimilars? That Would Be No Surprise To Analysts
Germany's Merck KGaA is reportedly making soundings to sell its biosimilar business to focus on its expanding pipeline.
Merck KGaA To Exit Biosimilars? That Would Be No Surprise To Analysts
Germany's Merck KGaA is reportedly making soundings to sell its biosimilar business to focus on its expanding pipeline.